Combining experimental and bioinformatics approaches, we evaluated the expression of CYP2A6 in HCC and assessed the correlation between the clinical features of HCC and the expression of CYP2A6 to evaluate its potential as a new HCC biomarker. The gene discussed is CYP2A6; the disease is hepatocellular carcinoma.